Abingdon Health lifts revenues 45% and targets profitable second half

An update from Abingdon Health PLC ( (GB:ABDX) ) is now available.

Abingdon Health reported unaudited first-half FY26 revenues of £4.5 million including grants, a 45% increase year-on-year, with reported revenue up 37% to £4.2 million and a reduced loss before tax of £2.3 million. The company said adjusted EBITDA remained negative at £1.7 million owing to investment in its cost base but expects the second half to deliver positive adjusted EBITDA and operating cash flow.

Growth was driven by its integrated CDMO and regulatory offering, with regulatory services revenues rising 49% to £1.9 million and several major CDMO contracts in execution, including recent U.S. deals worth $2.0 million and $2.5 million. Abingdon is expanding its Madison, Wisconsin operations, advancing sustainable product innovation with seaweed-based lateral flow housings, securing new IP for its AppDx smartphone reader and preparing for OTCQB trading, while maintaining FY26 revenue guidance at £12.6 million and signalling strong contract visibility into FY27.

The most recent analyst rating on (GB:ABDX) stock is a Hold with a £8.00 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.

Spark’s Take on ABDX Stock

According to Spark, TipRanks’ AI Analyst, ABDX is a Neutral.

Abingdon Health PLC’s overall stock score is primarily influenced by its mixed financial performance, with strong revenue growth overshadowed by profitability and cash flow challenges. The technical analysis indicates a neutral trend, lacking strong momentum. The valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a moderate overall score.

To see Spark’s full report on ABDX stock, click here.

More about Abingdon Health PLC

Abingdon Health plc is a UK-headquartered med-tech contract service provider specialising in lateral flow and other in vitro diagnostic technologies for an international customer base. Through its CDMO, analytical and regulatory service units in York, Doncaster and Madison, Wisconsin, the group develops, transfers and manufactures rapid diagnostic assays and supports regulatory approvals across markets including the U.S., EU and UK.

Its services span assay design, technology transfer and routine manufacturing, as well as performance evaluation and quality management consulting for diagnostics and medical devices. The group focuses on applications such as infectious disease, clinical and companion diagnostics, animal health and environmental testing, positioning Abingdon as an integrated, end-to-end partner from concept through to commercial scale-up.

Average Trading Volume: 173,430

Technical Sentiment Signal: Buy

Current Market Cap: £20.71M

See more data about ABDX stock on TipRanks’ Stock Analysis page.